| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2006;47:81.)
© 2006 American Heart Association, Inc.
Original Articles |
From the Nephrology and Hypertension Section (M.-S.Z., I.H.S., E.A.J., L.R.), Veterans Affairs Medical Center and Division of Nephrology and Hypertension and Vascular Biology Institute, University of Miami Miller School of Medicine, Miami, Fla; and Hypertension and Vascular Research Division (P.J.P.), Henry Ford Hospital, Detroit, Mich.
Correspondence to Leopoldo Raij, Nephrology-Hypertension Section, Veterans Affairs Medical Center, 1201 NW 16 St (Rm A-1009), Miami, FL 33125. E-mail LRaij{at}med.miami.edu
Endothelial dysfunction (ED) complicates hypertension and is a precursor of atherosclerosis. Reduced NO bioactivity, because of increased reduced NAD(P)H oxidasederived reactive oxygen species (ROS), plays a critical role in ED. gp91phox, predominantly expressed in the endothelium and adventitia, is a subunit of NAD(P)H oxidase important for its activation in response to angiotensin (Ang) II. Human atherosclerotic plaques are heavy laden with gp91phox. We have shown that in Dahl salt-sensitive (DS) rats, a paradigm of low renin salt-sensitive (SS) hypertension in humans, Ang II receptor blockade normalizes ROS production and endothelium-dependent relaxation (EDR) without significantly affecting systolic blood pressure (SBP). To additionally elucidate the mechanisms involved in the functional association of Ang II in SS hypertension, we administered a cell-permeable inhibitor of the assembly of p47phox with gp91phox in NAD(P)H oxidase, gp91ds-tat (10 mg/kg body weight, 3 weeks by minipump), to DS rats fed a 4% salt diet. Control rats received either vehicle or an inactive scramb-tat peptide. Vehicle-treated DS developed hypertension (SBP 168±5 mm Hg), left ventricular hypertrophy (LVH), proteinuria, impaired EDR, and increased aortic ROS production (superoxide 115% and peroxynitrite 157%) and expression of the proatherogenic molecules LOX-1 (130%) and MCP-1 (166%). gp91ds-tat, but not scramb-tat, normalized ROS and EDR, as well as LOX-1 and MCP-1, despite nonsignificant effects on SBP (159±5 mm Hg; P>0.05), left ventricular hypertrophy, and proteinuria. Our findings support the notion that in SS hypertension, activation of NAD(P)H oxidase promotes ED and atherogenesis via decreased nitric oxide bioactivity and increased LOX-1 and MCP-1, independent of blood pressure.
Key Words: endothelium sodium hypertension free radicals atherosclerosis
This article has been cited by other articles:
![]() |
M.-S. Zhou, I. H. Schulman, and L. Raij Role of angiotensin II and oxidative stress in vascular insulin resistance linked to hypertension Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H833 - H839. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-D. Liao, X.-P. Yang, Y.-H. Liu, E. G. Shesely, M. A. Cavasin, W. A. Kuziel, P. J. Pagano, and O. A. Carretero Role of Inflammation in the Development of Renal Damage and Dysfunction in Angiotensin II-Induced Hypertension Hypertension, August 1, 2008; 52(2): 256 - 263. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-S. Zhou, I. H. Schuman, E. A. Jaimes, and L. Raij Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-{beta}, and fibronectin with concomitant increase in nitric oxide bioavailability Am J Physiol Renal Physiol, July 1, 2008; 295(1): F53 - F59. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. J. Welch Angiotensin II-Dependent Superoxide: Effects on Hypertension and Vascular Dysfunction Hypertension, July 1, 2008; 52(1): 51 - 56. [Full Text] [PDF] |
||||
![]() |
D. D. Pearse, R.-X. Tian, J. Nigro, J. B. Iorgulescu, L. Puzis, and E. A. Jaimes Angiotensin II increases the expression of the transcription factor ETS-1 in mesangial cells Am J Physiol Renal Physiol, May 1, 2008; 294(5): F1094 - F1100. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. C Luft The Bothrops legacy: Vasoactive peptides from Brazil Journal of Renin-Angiotensin-Aldosterone System, March 1, 2008; 9(1): 57 - 64. [PDF] |
||||
![]() |
E. A. Jaimes, M.-S. Zhou, D. D. Pearse, L. Puzis, and L. Raij Upregulation of cortical COX-2 in salt-sensitive hypertension: role of angiotensin II and reactive oxygen species Am J Physiol Renal Physiol, February 1, 2008; 294(2): F385 - F392. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. A. Korshunov, M. Daul, M. P. Massett, and B. C. Berk Axl Mediates Vascular Remodeling Induced by Deoxycorticosterone Acetate Salt Hypertension Hypertension, December 1, 2007; 50(6): 1057 - 1062. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Muthumala, H. Montgomery, J. Palmen, J. A. Cooper, and S. E. Humphries Angiotensin-Converting Enzyme Genotype Interacts With Systolic Blood Pressure to Determine Coronary Heart Disease Risk in Healthy Middle-Aged Men Hypertension, August 1, 2007; 50(2): 348 - 353. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. H. Schulman, M.-S. Zhou, E. A. Jaimes, and L. Raij Dissociation between metabolic and vascular insulin resistance in aging Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H853 - H859. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Morawietz LOX-1 and Atherosclerosis: Proof of Concept in LOX-1-Knockout Mice Circ. Res., June 8, 2007; 100(11): 1534 - 1536. [Full Text] [PDF] |
||||
![]() |
M.-S. Zhou Upregulation of Nitric Oxide, Inhibition of Oxidative Stress, and Antihypertensive Effects of Statins Hypertension, June 1, 2007; 49(6): e43 - e43. [Full Text] [PDF] |
||||
![]() |
Z. Wang, I. Armando, L. D. Asico, C. Escano, X. Wang, Q. Lu, R. A. Felder, C. G. Schnackenberg, D. R. Sibley, G. M. Eisner, et al. The elevated blood pressure of human GRK4{gamma} A142V transgenic mice is not associated with increased ROS production Am J Physiol Heart Circ Physiol, May 1, 2007; 292(5): H2083 - H2092. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Hernandez Schulman, M.-S. Zhou, and L. Raij Cross-Talk Between Angiotensin II Receptor Types 1 and 2: Potential Role in Vascular Remodeling in Humans Hypertension, February 1, 2007; 49(2): 270 - 271. [Full Text] [PDF] |
||||
![]() |
T. M. Paravicini and R. M. Touyz Redox signaling in hypertension Cardiovasc Res, July 15, 2006; 71(2): 247 - 258. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |